Vanop LSE forum (Poidster)
Iedereen zit met de vraag: Hoe gaat dit verder evolueren?
Hoelang gaan we testen? Wat gaan we testen?
Hoe kan Nova hier aan deel nemen of op inspelen? Wat zijn de opportuniteiten na covid enz....
De volgende (engelse) teskst geeft een aantal mogelijkheden!
Covid is now with us, it will just turn into a cyclical endemic infection like influenza. Also the Q32 platform is a methodology, its not specific to Covid, Winterplex is a 1 shot respiratory panel covering Flu Viruses, RSV and Covid.. There will be a high demand globally, year round (as the flu season circles the globe during the year) for highly specific and sensitive assays that are timely and high volume.
This repetoire with expand over time @Primerdesign have already shown themselves to be agile and skilled enough to bring new assays on line quickly.
This is also not just linked to infectious diseases, There are other completely unrelated fields of medicine that could benefit from a quick reliable PCR assay.
So NYCT have the versatile platform that is proven to be reliable and of high sensitivity/specificity and is becoming a Gold Standard
They have a very agile, capable development team that can respond quickly to developing trends (Look how quickly they developed a test for the mink variant,
This is a developing branch of pathology medicine. Lots of labour intensive skilled tasks are now being superseded by PCR.
So, they are far from a 1 trick pony.
Future developments of PROmate, Versalab and , hopefully, an increase in capacity for the Q32 to a Q64 or even a Q128 with automation would mean they have a platform of analysers that would be suitable for POCT and main diagnostic labs too.
The winterplex, if they can bring the testing kits in at a reasonable price.
I'm not seeing many downsides atm, don't forget that this is a global market too, the demand will be there DYOR